Help us reuse, reduce and recycle Dysport packaging
While the expanded polystyrene (EPS) packaging does an excellent job of insulating and protecting Dysport during shipping, it can become a large volume of waste material at your office and your local landfill. Help promote a cleaner and greener environment by recycling Dysport foam packaging instead of tossing it in the trash.
EPS packaging drop-off locations
The EPS Industry Alliance currently has a network of more than 200 collection sites across the United States. Find one in your area today.
Find an EPS drop-off location
AFPR national mail-back recycling locations
If an EPS recycling location is not available in your community, you may be able to participate in the Alliance of Foam Packaging Recyclers (AFPR) National Mail-Back Recycling program.
Find AFPR mail-back location
Packaging recycling information
Our packaging supplier, Cold Chain Technologies, is helping to preserve and protect the environment from the start through more sustainable manufacturing processes. Learn more about their products and recycling initiatives.
Discover Cold Chain Technologies recycling
IMPORTANT SAFETY INFORMATION
Indication: Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients ˂65 years of age.
Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.
- Hypersensitivity to any botulinum toxin product or excipients
- Allergy to cow’s milk protein
- Infection at the proposed injection site(s)
Warnings and Precautions
- The potency Units of Dysport are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products.
- Recommended dose and frequency of administration should not be exceeded.
- Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties.
- Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.
- Dysport contains human albumin. There is a risk for transmission of Creutzfeldt-Jakob disease (CJD) however, no cases of transmission of viral diseases or CJD have ever been identified for albumin.
- In clinical studies, the most frequently reported adverse events (≥2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, nausea, and blood present in urine.
- Concomitant use of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of the botulinum toxin may be potentiated.
- Anticholinergic drugs may potentiate systemic anticholinergic effects.
- Excessive weakness may be exacerbated by administration of different botulinum neurotoxins and/or muscle relaxants during the course of treatment with Dysport.
Use in Specific Populations
Dysport is not recommended for use in children or pregnant women
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Dysport Full Prescribing Information, including Medication Guide.